



September 18, 2008

Suzuken Co., Ltd.

Hiroshi Ota, President and CEO

Stock Code: 9987

Securities Traded: First sections of Tokyo and Nagoya stock exchanges, and Sapporo
Stock Exchange

Contact: Takahito Ito, Senior Executive Officer, Senior General Manager, Corporate
Planning Headquarters and Administrative Headquarters

Tel: +81-52-961-2331

**Suzuken Co., Ltd Announces the Acquisition of Shares in Pfercos
(Conclusion of a Share Transfer Contract)**

Suzuken Co., Ltd (hereinafter referred to as “Suzuken”) hereby announces that it recently concluded an agreement, described below, with NIC Corporation (hereinafter referred to as “NIC”) on the acquisition of shares in Pfercos Co., Ltd. (an ethical pharmacy business; hereinafter referred to as “Pfercos”), a consolidated subsidiary of NIC.

1. The purpose of the share acquisition

Suzuken is focused on the “establishment of a medical distribution platform” as its medium-term vision and is aiming to be of service to all healthcare-related people by taking on functions across the whole of medical distribution, from pharmaceutical companies to medical facilities and insurance pharmacies and even to patients themselves.

In such an environment, the company believes that in order to establish a medical distribution platform, it needs to fuse the business infrastructure and know-how of Pfercos with Suzuken’s distribution operations and has reached agreement with NIC for the company to acquire the shares that NIC owns in Pfercos.

2. Share acquisition schedule

September 18, 2008	Board of Directors resolution, conclusion of share transfer agreement
October 1, 2008	Date of acquisition of shares (planned)

3. Number of shares to be acquired

2,975 shares (proportion of shares to be held after the transfer: 45.4%, proportion of shareholder voting rights held: 51.5%)

Separate to the above, Suzuken plans to acquire 375 shares in Pfercos that are held by individuals and plans to convert Pfercos into a subsidiary of the company on October 1, 2008.

(Proportion of shares to be held after the transfer: 51.1%, proportion of shareholder voting rights held: 58.0%)

4. Overview of the companies involved

(As of March 31, 2008)

(1) Company name	Suzuken Co., Ltd.	NIC Corporation	Pfercos Co., Ltd.
(2) Description of business	Wholesaling of ethical drugs, etc.	Medicine-related contract business, educational business, welfare business	Ethical pharmacy business
(3) Date of establishment	August 10, 1946	October 2, 1968	February 2, 1993
(4) Head office address	8 Higashi Kataha-machi Higashi-ku, Nagoya	3-2 Kanda Sakuma-cho, Chiyoda-ku, Tokyo	2nd Fl., Murataya Bldg, 68 Kanda Neribeicho, Chiyoda-ku, Tokyo
(5) Representative	Hiroshi Ota, President and CEO	Osamu Tsuchiya, President and CEO	Mitsuaki Shimada, President and CEO
(6) Capital	¥13,546 million	¥6,184 million	¥382 million
(7) Number of outstanding shares	93,949,167 shares	12,400,689 shares (Note)	6,550 shares
(8) Number of employees	4,615	11,244	523
(9) Main shareholders and shareholding ratios	Japan Trustee Services Bank, Ltd. (Shionogi & Co., Ltd., retirement benefit trust account re-entrusted by Sumitomo Trust and Banking Co., Ltd.) 5.74%, Japan Trustee Services Bank, Ltd. (Trust account) 4.73% Citibank Singapore Barclays Bank (Suisse) SA 4.59%	Katsuyoshi Niimura 9.82% Meiji Yasuda Life Insurance Company 7.64% Kenshoh Co., Ltd 7.12%	NIC Corporation 82.44%

(Note) NIC carried out a 1-for-2 share split of common shares in April 1, 2008, based on a resolution of the Meeting of the Board of Directors held on February 21, 2008. By doing so, the number of outstanding shares in the company as of April 1, 2008 doubled to 24,801,378 shares.

(10) Pfercos Results Term ending March 2008

Sales	¥14,816 million
Operating profit	¥603 million
Ordinary profit	¥607 million
Current term net profit	¥274 million

5. Consolidated results outlook

The impact on consolidated results associated with this share transfer will be minor.